S-Alpha Therapeutics is a company that researches and develops digital health solutions including digital therapeutics, a clinically proven next-generation treatment.
S-Alpha Therapeutics provides medical services by discovering treatment mechanisms in various disease areas such as ophthalmology, immunology, and oncology, and developing medical device software through these treatments.

Wellness digital therapy device (S-Mune), an influenza vaccine adjuvant
S-Alpha Therapeutics recently developed S-Mune, a wellness digital therapy device, as an influenza vaccine adjuvant.
S-Mune is currently undergoing the FDA registration process. Vaccine adjuvants are defined as substances added to vaccines to improve the immunogenicity of the vaccine and induce a strong immune response.

To prevent influenza virus infection, it is important to control factors that affect the immune response. Vaccines are designed to activate different types of immune cells to produce an effective immune response. Various studies on exercise and the body’s immune response have shown that exercise regulates NK cells that kill virus-infected cells through the natural immune system, and that regular exercise increases anti-inflammatory cytokines, including Interleukin-10 (IL-10).
S-Mune is designed to improve the immune response by inducing appropriate activity in the users, who can improve the effectiveness of the influenza vaccine by using this device. Clinical results showed that the S-Mune group had increased and maintained anti-influenza antibody levels after vaccination compared to the control group. A paper related to S-Mune’s effectiveness verification data was published on the Immune Network, and was presented at academic conferences.

“We seek to provide solutions to diseases for members of society by discovering and developing treatments for disease areas for which treatments have not been developed thus far,” the company’s representative explained.
korean-electronics.com | Blog Magazine of korean electronics, brands and Goods






